Robertson Stephens Wealth Management LLC Has $2.89 Million Stake in Danaher Corporation $DHR

Key Points

• Robertson Stephens Wealth Management LLC reduced its stake in Danaher Corporation by 8.2% in Q2, leaving it with shares worth $2.89 million.
• In the first quarter, several major hedge funds, including Vanguard Group and Invesco Ltd., increased their stakes in Danaher, indicating strong institutional interest with 79.05% of the stock owned by institutions.
• Danaher has declared a quarterly dividend of $0.32, representing an annualized yield of 0.6%, with the ex-dividend date set for September 26th.

Robertson Stephens Wealth Management LLC trimmed its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 8.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,611 shares of the conglomerate's stock after selling 1,304 shares during the period. Robertson Stephens Wealth Management LLC's holdings in Danaher were worth $2,891,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in DHR. Vanguard Group Inc. increased its stake in shares of Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. Invesco Ltd. increased its stake in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Danaher by 4.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock worth $867,168,000 after purchasing an additional 163,332 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 11.10% of the company's stock.

Danaher Trading Down 1.0%

Shares of DHR opened at $202.53 on Friday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.41. The business's fifty day moving average is $200.66 and its 200-day moving average is $197.25. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market cap of $145.02 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 2.91 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the company posted $1.72 EPS. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DHR shares. Rothschild Redb lowered Danaher from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. UBS Group dropped their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Rothschild & Co Redburn reiterated a "neutral" rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research report on Wednesday. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, Danaher currently has an average rating of "Moderate Buy" and an average target price of $244.60.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.